Pharmaceutical

STAT+: In early trial, drug appears to reduce harmful p...

An early trial of a drug offer hope for people with ATTR-CM, a type of heart dis...

STAT+: Soft, stretchable electronic skin could reconstr...

A Stanford team has built soft, stretchable electronic skin that aims to restore...

STAT+: After new cluster, health officials warn mpox co...

Mpox has “a substantial risk of resurgence” health officials say, warning people...

Cost of disease-modifying therapies for multiple sclero...

While MS is not a terminal diagnosis, the effect of the disease on the CNS can s...

US FDA accepts Satsuma’s 505(b)(2) NDA for STS101

The NDA was supported by data obtained from the Phase I clinical trial and the P...

Myeloid raises funds to support lead cell therapy progr...

The financing will help to fast-track the development of other in vivo programmi...

Treatment options for Crohn’s disease expand after Rinv...

AbbVie’s blockbuster drug Rinvoq earned its seventh approval to become the first...

Supreme Court backs Sanofi in high-profile cholesterol ...

The justices’ verdict concludes a long legal battle between the companies over p...

Oncology biosimilar case studies: rituximab biosimilars

The first approved biosimilar in the US and EU was Celltrion/Teva Pharmaceutical...

OncoResponse receives CPRIT grant to advance OR502

OR2805 was discovered using the company’s B cells discovery platform.

SiteOne secures funding from NIDA for non-opioid therap...

The grant is a UG3/UH3 phase innovation awards co-operative agreement in two pha...

Alimera Sciences buys US rights to EyePoint’s Yutiq

Yutiq received the US Food and Drug Administration's approval in October 2018.

US FDA approves Bausch + Lomb and Novaliq’s DED treatm...

Miebo is the first and only prescription eye drop to receive approval from the F...

STAT+: In its first tough test, CRISPR epigenome editin...

The Tune Therapeutics results are the first published data showing successful CR...

STAT+: 1 in 5 primary endpoints changed in late-stage t...

The findings raised questions about the quality of the clinical trials, as well ...

STAT+: FDA advisers vote against approving Intercept’s ...

A panel of expert advisers to the FDA voted against approving Intercept Pharmace...